Dendreon CEO resigns

Share this article:

Dendreon CEO John Johnson is calling it quits. The Seattle manufacturer of prostate cancer drug Provenge announced Monday that Johnson was leaving for personal reasons. Douglas Watson has replaced Johnson as chairman of the board. Johnson will remain president and CEO through August 15.

The Street's Adam Feuerstein noted Monday that Johnson is leaving the beleaguered company as it is subsumed by debt, and says the company will make its June $28 million payment, but “has no means to pay the $560 million in debt due in 2016.”

Johnson was named CEO in February 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.